Literature DB >> 21139506

Double-dose gadoxetic Acid-enhanced magnetic resonance imaging in patients with chronic liver disease.

Utaroh Motosugi1, Tomoaki Ichikawa, Katsuhiro Sano, Hironobu Sou, Kojiro Onohara, Ali Muhi, Takatoshi Kitamura, Fumitake Amemiya, Nobuyuki Enomoto, Masanori Matsuda, Masami Asakawa, Hideki Fujii, Tsutomu Araki.   

Abstract

OBJECTIVES: determine the effect of double-dose gadoxetic-acid (Gd-EOB-DTPA) on lesion-liver contrast ratio in arterial- and hepatocyte-phase images and arterial-phase image quality in patients with chronic liver disease.
MATERIALS AND METHODS: the ethics committee at our institute approved this study. This study included 28 patients (13 with Child-Pugh class A and 15 with class B) with 54 hepatocellular carcinomas. All patients received the standard Gd-EOB-DTPA dose (0.025 mmol/kg bodyweight) and double dose (0.050 mmol/kg bodyweight). The lesion-liver contrast ratio was evaluated in arterial- and hepatocyte-phase images. The artifacts in arterial-phase images were evaluated with a 4-point scale. Wilcoxon signed-rank test were used for comparisons.
RESULTS: the hepatocyte-phase lesion-liver contrast ratio after the double dose was significantly higher than that after the standard dose in patients with Child-Pugh class B disease(standard dose vs. double dose; 0.20 ± 0.16 vs. 0.25 ± 0.17; P < 0.0001); however, the ratio after both the standard and double doses was equivalent in patients with Child-Pugh class A disease (0.35 ± 0.18 vs. 0.35 ± 0.14; P = 0.3038). The double dose significantly increased the arterial-phase lesion-liver contrast ratio (0.34 ± 0.19 vs. 0.58 ± 0.33; P < 0.0001). The artifacts in the arterial-phase images were more prominent after the standard dose (2.7 vs. 2.4 for reader 1, 2.8 vs. 2.4 for reader 2; P = 0.0195 and 0.0010).
CONCLUSIONS: administration of double dose of Gd-EOB-DTPA provided better arterial enhancement of hepatocellular carcinomas in patients with chronic liver disease, and also improved the lesion-liver contrast in hepatocyte-phase images in patients with Child-Pugh class B disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21139506     DOI: 10.1097/RLI.0b013e3181f9c487

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  22 in total

1.  High resolution navigated three-dimensional T₁-weighted hepatobiliary MRI using gadoxetic acid optimized for 1.5 Tesla.

Authors:  Scott K Nagle; Reed F Busse; Anja C Brau; Jean H Brittain; Alex Frydrychowicz; Yuji Iwadate; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2012-05-30       Impact factor: 4.813

2.  Added value of gadoxetic acid-enhanced T1-weighted magnetic resonance cholangiography for the diagnosis of post-transplant biliary complications.

Authors:  Sonja Kinner; Tilman B Schubert; Adnan Said; Joshua D Mezrich; Scott B Reeder
Journal:  Eur Radiol       Date:  2017-04-13       Impact factor: 5.315

3.  Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3 tesla: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid.

Authors:  Alex Frydrychowicz; Scott K Nagle; Sharon L D'Souza; Karl K Vigen; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2011-07-12       Impact factor: 4.813

4.  The inhibitory effect of gadoxetate disodium on hepatic transporters: a study using indocyanine green.

Authors:  Hiroyuki Akai; Koichiro Yasaka; Akira Kunimatsu; Masanori Nojima; Yusuke Inoue; Osamu Abe; Kuni Ohtomo; Shigeru Kiryu
Journal:  Eur Radiol       Date:  2018-04-12       Impact factor: 5.315

5.  Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A.

Authors:  Derek J Erstad; Ian A Ramsay; Veronica Clavijo Jordan; Mozhdeh Sojoodi; Bryan C Fuchs; Kenneth K Tanabe; Peter Caravan; Eric M Gale
Journal:  Invest Radiol       Date:  2019-11       Impact factor: 6.016

6.  Second shot arterial phase to overcome degraded hepatic arterial phase in liver MR imaging.

Authors:  Yang Shin Park; Jongmee Lee; Jeong Woo Kim; Cheol Min Park; Chang Hee Lee
Journal:  Eur Radiol       Date:  2018-12-14       Impact factor: 5.315

7.  An Investigation of Transient Severe Motion Related to Gadoxetic Acid-enhanced MR Imaging.

Authors:  Utaroh Motosugi; Peter Bannas; Candice A Bookwalter; Katsuhiro Sano; Scott B Reeder
Journal:  Radiology       Date:  2015-10-16       Impact factor: 11.105

Review 8.  Gd-EOB-DTP-enhanced MRC in the preoperative percutaneous management of intra and extrahepatic biliary leakages: does it matter?

Authors:  Mario Petrillo; Anna Maria Ierardi; Laura Tofanelli; Duilia Maresca; Alessio Angileri; Francesca Patella; Gianpaolo Carrafiello
Journal:  Gland Surg       Date:  2019-04

9.  Comparison of hepatocellular carcinoma conspicuity on hepatobiliary phase images with gadoxetate disodium vs. delayed phase images with extracellular cellular contrast agent.

Authors:  So Yeon Kim; En-Haw Wu; Seong Ho Park; Z Jane Wang; Thomas A Hope; Judy Yee; Li-Qin Zhao; Wei-Chou Chang; Benjamin M Yeh
Journal:  Abdom Radiol (NY)       Date:  2016-08

10.  Combined gadoxetic acid and gadofosveset enhanced liver MRI for detection and characterization of liver metastases.

Authors:  Peter Bannas; Candice A Bookwalter; Tim Ziemlewicz; Utaroh Motosugi; Alejandro Munoz Del Rio; Theodora A Potretzke; Scott K Nagle; Scott B Reeder
Journal:  Eur Radiol       Date:  2016-04-30       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.